Elizabeth Schneider: Revolutionary Drug Shows Promise for Primary Ovarian Insufficiency
Elizabeth Schneider, Staff Product Marketing Manager at Illumina, shared a post on LinkedIn:
“Primary ovarian insufficiency (POI), in which the ovaries don’t mature and release eggs properly, affects about 3% of women under age 40 and typically causes infertility. But a drug already approved to treat kidney disease may one day help some of these people get pregnant, a research team reports today in Science.
In studies of mouse ovarian tissue and live mice, the drug, called finerenone, kick-started the growth of tiny egg-containing sacs, or follicles—a process that’s often defunct in people with POI. In a small clinical trial, people with POI who were given the drug went on to produce mature eggs that could be harvested, and some of the eggs were then successfully fertilized in the lab.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jun 24, 2026, 14:30Highlights From the ASRM/CFAS Business of Medicine Conference 2026 – ASRM
-
Jun 24, 2026, 14:26Smit Bharat Solanki: The Most Important Part of a Myomectomy Happens Before Surgery
-
Jun 24, 2026, 13:56Mario Lumbreras Marquez: Maternal and Perinatal Outcomes in Pregnancy with High PAH Risk
-
Jun 24, 2026, 13:54Creating Psychologically Safe Teams in High-Pressure Healthcare – RCOG
-
Jun 24, 2026, 13:36Marco Zaccaria: The Countdown to GCH2027 Begins Now!
-
Jun 24, 2026, 13:34Surgical Approach to Reduce the Risks of Intraoperative Complications and Postpartum Hemorrhage – IJGO
-
Jun 24, 2026, 13:10How One Follicle Can Vanish or Produce an Aged Egg During IVF? – Fertility Plus
-
Jun 24, 2026, 12:41ACSC2026 Day Two Focuses on Women’s Rights and Respectful Maternity Care – SOGC
-
Jun 24, 2026, 08:13Ongoing Gaps in Contraceptive Access and Experience – BPAS